Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 24;21(2):189–202. doi: 10.1007/s40268-021-00343-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 2 — Diagram of final structural pharmacokinetic model for ManNAc and Neu5Ac. F oral bioavailability, k_a first-order oral absorption rate-constant for exogenously administered ManNAc (h⁻¹), k_syn zero-order endogenous production rate constant for ManNAc (μg/h), CMT compartment, CL_M apparent clearance for ManNAc (L/h), M₀ initial endogenous plasma ManNAc concentration (ng/mL), V_M apparent volume of distribution for ManNAc (L), k_pro zero-order production rate constant for Neu5Ac in precursor compartment (ng/mL·h), Pre-Neu5Ac Neu5Ac precursor, k_out first-order elimination rate constant for Neu5Ac (h⁻¹), N₀ initial endogenous plasma Neu5Ac concentration (ng/mL)